Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Oxycodon und Naloxon, ATC N02AA55

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 583 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Oxycodon und Naloxon, ATC N02AA55

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

Automatic termination if a subsequent nationwide or regional rebate contract is concluded for the same active substance...

No estimated contract value disclosed; potential low volume or uncertain revenue.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Supply of pharmaceutical products containing Oxycodon and Naloxon (ATC N02AA55)
  • Entering into non-exclusive rebate agreements with AOK Bayern
Afficher le résumé complet

Open-house model for non-exclusive pharmaceutical rebate agreements for Oxycodon and Naloxon (ATC N02AA55) with AOK Bayern. All interested pharmaceutical companies meeting eligibility can sign identical, non-negotiable contracts from June 1, 2026 to May 31, 2028. No competitive selection; any eligible company can join at any time until April 3, 2028. Estimated value not provided.

Risques

Automatic termination if a subsequent nationwide or regional rebate contract is concluded for the same active substance...

No estimated contract value disclosed; potential low volume or uncertain revenue.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential partners

Administrative

  • Contract must be signed with qualified electronic signature or submitted in paper form with handwritten signature
  • Declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; all eligible participants are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Oxycodon und Naloxon, ATC N02AA55

Non-exclusive rebate agreements for active substances Oxycodon and Naloxon (ATC N02AA55). All eligible pharmaceutical companies can participate. Contracts run from June 1, 2026 to May 31, 2028. Submission via communication area on www.dtvp.de.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; all eligible participants are accepted.

Date limite

Deadline Apr 03, 2028

Détails de la procédure

Date de publication
14 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
255858-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30